Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
March 04 2021 - 4:05PM
Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical
company focused on treatments for gastrointestinal (GI) disorders
and diseases, today announced that the Company is scheduled to
release its fourth quarter and full year 2020 financial results on
Thursday, March 11, 2021, after the market closes.
Evoke will host a conference call on Thursday,
March 11, 2021, at 4:30 p.m. ET to discuss the results. The dial-in
numbers for the conference call are (877) 473-1186 for domestic
callers and (918) 922-6138 for international callers. The
conference ID number is 4193567.
In addition, a telephonic replay of the call
will be available until March 18, 2021. The replay dial-in numbers
are (855) 859-2056 for domestic callers and (404) 537-3406 for
international callers. Please use the replay conference ID number
4193567.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company
focused primarily on the commercialization and development of drugs
to treat GI disorders and diseases. The Company developed GIMOTI, a
nasal spray formulation of metoclopramide, for the relief of
symptoms associated with acute and recurrent diabetic gastroparesis
in adults.
Diabetic gastroparesis is a GI disorder
affecting millions of patients worldwide, in which the stomach
takes too long to empty its contents resulting in serious GI
symptoms as well as other systemic complications. The gastric delay
caused by gastroparesis can compromise absorption of orally
administered medications. Prior to FDA approval to commercially
market GIMOTI, metoclopramide was only available in oral and
injectable formulations and remains the only drug currently
approved in the United States to treat gastroparesis.
Safe Harbor Statement
Evoke cautions you that statements included in
this press release that are not a description of historical facts
are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negatives of these
terms or other similar expressions. These statements are based on
Evoke’s current beliefs and expectations. These
forward-looking statements include statements regarding Evoke’s
anticipated use of proceeds from the offering. The
inclusion of forward-looking statements should not be regarded as a
representation by Evoke that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Evoke’s
business, including those described in Evoke’s periodic filings
with the SEC and the prospectus supplement and related prospectus
for this offering filed with the SEC. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and Evoke undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Investor Contact:The Ruth GroupJames
SaliernoTel: 973-255-8361jsalierno@theruthgroup.com
Media Contact:The Ruth GroupAnnika ParrishTel:
720-412-9042aparrish@theruthgroup.com
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Sep 2023 to Sep 2024